To the full analysis
Buyback calculator for Spyre Therapeutics
Spyre Therapeutics stock: key metrics
SYRESpyre Therapeutics had an operating margin of 0% and a return on invested capital (ROIC) of −26% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2014 | no data | no data | no data |
| 2015 | 0.0% | −185.9% | −185.6% |
| 2016 | 0.0% | −473.3% | −468.8% |
| 2017 | 0.0% | −531.7% | −523.3% |
| 2018 | 0.0% | −1,169.3% | −1,140.6% |
| 2019 | no data | no data | no data |
| 2020 | no data | no data | no data |
| 2021 | 100.0% | −350.3% | −351.1% |
| 2022 | 100.0% | −3,640.2% | −3,598.8% |
| 2023 | 100.0% | −27,348.0% | −38,238.1% |
| 2024 | no data | no data | no data |
| 2025 | no data | no data | no data |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2014 | −100.0% | no data | −100.0% |
| 2015 | −31.3% | −47.0% | −29.2% |
| 2016 | −34.5% | −34.9% | −32.4% |
| 2017 | −54.1% | −38.5% | −48.6% |
| 2018 | −65.8% | −60.9% | −57.0% |
| 2019 | −100.0% | −95.9% | −94.1% |
| 2020 | −57.9% | −61.3% | −50.1% |
| 2021 | −78.4% | −44.1% | −59.9% |
| 2022 | −100.0% | −91.6% | −100.0% |
| 2023 | −100.0% | no data | −99.1% |
| 2024 | −40.2% | −38.1% | −34.2% |
| 2025 | −21.7% | −26.0% | −20.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2017)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.